MSB 2.03% $1.45 mesoblast limited

FDA ODAC Meeting Material discussion analysis, page-345

  1. 1,609 Posts.
    lightbulb Created with Sketch. 1691
    Such great timing.

    In what world does the FDA reject Ryoncil for AGVHD but approve Rem-L for COVID ARDS?

    I suppose it's possible, of course, but seriously, that would be the FDA shredding the little credibility it has left after this year's various COVID-related debacles.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.